|
Dr. Johnson is a founder and president and CEO of Emiliem, Inc., a biotechnology company in the San Francisco Bay Area that focuses on creating new oncology therapeutics. He has over 25 years of experience in biotechnology and pharmaceutical research and development activities, in which he has led and managed groups ranging from small units in start-up companies to multinational units in large corporations. Dr. Johnson has participated in the research and development of over 100 compounds of which 15 have become marketed healthcare medicinal products in the United States and Europe. Most recently, he served as vice president, drug assessment & cevelopment at Chiron Corporation and previously as vice president, preclinical development. Prior research and development positions include Hoechst-Roussel Pharmaceuticals, Inc., International Research and Development Corp. (a preclinical CRO), Lederle (American Cyanamid), and Eos Biotechnology. Dr. Johnson received his PhD in toxicology from the University of Michigan where he was awarded an AFPE Fellowship. Before his PhD studies, he received a BS and a PharmD from the University of Michigan and completed a clinical pharmacy residency at UM Medical Center where he was awarded the National Resident of the Year Award. He is a diplomate of the American Board of Toxicology and serves as a member of industry and government advisory boards. Dr. Johnson is co-editor of the journals The Chemistry of Metabolic and Toxicological Processes and Current Opinion in Drug Discovery & Development and is an adjunct professor in molecular toxicology at University of California, Berkeley, where he teaches computational toxicology. | 